Prevalence and predictors of polypharmacy in elderly patients discharged from a tertiary care teaching hospital in Swat, Pakistan: A retrospective cross-sectional study
DOI:
https://doi.org/10.46542/pe.2024.243.16Keywords:
Elderly, Pakistan, Polypharmacy, Prevalence, Risk factorAbstract
Background: The use of polypharmacy in the elderly has been the subject of much consideration in recent years. However, its prevalence and risk factors are yet to be properly investigated in Pakistan.
Objective: The study investigated the prevalence and risk factors of polypharmacy at discharge in Pakistan.
Method: A retrospective cross-sectional study of elderly patients' medical profiles for the year 2021 was performed, and the profiles that met the inclusion criteria were included.
Results: The total sample size was 800, and 51.9% of patients received polypharmacy at discharge. The authors found that the female gender (OR = 0.469) has comparatively less risk of receiving polypharmacy. Furthermore, patients with an increased length of stay and increased medication use in the hospital (OR 1.1295, OR = 17.189, respectively) have a high risk of receiving polypharmacy at discharge. Furthermore, patients diagnosed with peripheral vascular disease (OR = 4.689), cerebrovascular accident (OR = 2.764), chronic obstructive pulmonary disease (OR = 3.748), asthma (OR = 2.321), and diabetes mellitus (OR = 2.754) had higher risks of receiving polypharmacy.
Conclusion: The study found a high prevalence of polypharmacy at discharge in Pakistan and identified several risk factors that could help to reduce polypharmacy by targeting vulnerable groups.
References
Aggarwal, P., Woolford, S. J., & Patel, H. P. (2020). Multi-morbidity and polypharmacy in older people: Challenges and opportunities for clinical practice. Geriatrics, 5(4), 85. https://doi.org/10.3390/geriatrics5040085
Ahmed, B., Nanji, K., Mujeeb, R., & Patel, M. J. (2014). Effects of polypharmacy on adverse drug reactions among geriatric outpatients at a tertiary care hospital in Karachi: A prospective cohort study. PLoS ONE, 9(11), e112133. https://doi.org/10.1371/journal.pone.0112133
Appleton, S. C., Abel, G. A., & Payne, R. A. (2014). Cardiovascular polypharmacy is not associated with unplanned hospitalisation: Evidence from a retrospective cohort study. BMC Family Practice, 15(1), 58. https://doi.org/10.1186/1471-2296-15-58
Bourgeois, F. T., Shannon, M. W., Valim, C., & Mandl, K. D. (2010). Adverse drug events in the outpatient setting: An 11-year national analysis. Pharmacoepidemiology and Drug Safety, 19(9), 901–910. https://doi.org/10.1002/pds.1984
Díez-Manglano, J., Barquero-Romero, J., Mena, P. A., Recio-Iglesias, J., Cabrera-Aguilar, J., López-García, F., Viu, R. B., Soriano, J. B., & Researchers, the E. S. (2014). Polypharmacy in patients hospitalised for acute exacerbation of COPD. European Respiratory Journal, 44(3), 791–794. https://doi.org/10.1183/09031936.00014814
Faisal, S., Zairina, E., Nathishuwan, S., Khotib, J., Ari Kristina, S., & Nugraheni, G. (2013). Prevalence and predictors of excessive polypharmacy in geriatric inpatients: A retrospective cross-sectional study in Indonesia. Journal of Primary Care & Community Health, 14(1-9). https://doi.org/10.1177/21501319231178595
Franssen, F., Spruit, M., & Wouters. (2011). Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease, 2011(6), 493–501. https://doi.org/10.2147/copd.s24443
Gallagher, P., Barry, P., & O'Mahony, D. (2007). Inappropriate prescribing in the elderly. Journal of Clinical Pharmacy and Therapeutics, 32(2), 113–121. https://doi.org/10.1111/j.1365-2710.2007.00793.x
Gillette, C., Prunty, L., Wolcott, J., & Broedel-Zaugg, K. (2015). A new lexicon for polypharmacy: Implications for research, practice, and education. Research in Social and Administrative Pharmacy, 11(3), 468–471. https://doi.org/10.1016/j.sapharm.2014.08.010
Grant, R. W., Cagliero, E., Murphy-Sheehy, P., Singer, D. E., Nathan, D. M., Meigs, J. B. (2002). Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. The American Journal of Medicine, 112(8), 603–609. https://doi.org/10.1016/S0002-9343(02)01103-8
Haider, S. I., Johnell, K., Thorslund, M., & Fastbom, J. (2007). Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992-2002. International Journal of Clinical Pharmacology and Therapeutics, 45(12), 643–653. https://doi.org/10.5414/cpp45643
Haider, S. I., Johnell, K., Thorslund, M., & Fastbom, J. (2008). Analysis of the association between polypharmacy and socioeconomic position among elderly aged ≥77 years in Sweden. Clinical Therapeutics, 30(2), 419–427. https://doi.org/10.1016/j.clinthera.2008.02.010
Harugeri, A., Joseph, J., Parthasarathi, G., Ramesh, M., & Guido, S. (2010). Prescribing patterns and predictors of high-level polypharmacy in the elderly population: A prospective surveillance study from two teaching hospitals in India. The American Journal of Geriatric Pharmacotherapy, 8(3), 271–280. https://doi.org/10.1016/j.amjopharm.2010.06.004
Jyrkkä, J., Enlund, H., Lavikainen, P., Sulkava, R., & Hartikainen, S. (2011). Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiology and Drug Safety, 20(5), 514–522. https://doi.org/10.1002/pds.2116
Khezrian, M., McNeil, C. J., Murray, A. D., & Myint, P. K. (2020). An overview of prevalence, determinants and health outcomes of polypharmacy. Therapeutic Advances in Drug Safety, 11(11), 204209862093374. https://doi.org/10.1177/2042098620933741
Kojima, T., Akishita, M., Nakamura, T., Nomura, K., Ogawa, S., Iijima, K., Eto, M., & Ouchi, Y. (2011). Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatrics & Gerontology International, 12(3), 425–430. https://doi.org/10.1111/j.1447-0594.2011.00783.x
Martikainen, J. E., & Enlund, H. (2009). New chemical entities and their market penetration in Finland during the years 1996 through 2005. Clinical Therapeutics, 31(3), 668–676. https://doi.org/10.1016/j.clinthera.2009.03.016
Masnoon, N., Shakib, S., Kalisch-Ellett, L., & Caughey, G. E. (2017). What is polypharmacy? A systematic review of definitions. BMC Geriatrics, 17(1), 230. https://doi.org/10.1186/s12877-017-0621-2
Maxwell, C. J., Mondor, L., Pefoyo Koné, A. J., Hogan, D. B., & Wodchis, W. P. (2021). Sex differences in multimorbidity and polypharmacy trends: A repeated cross-sectional study of older adults in Ontario, Canada. PLOS ONE, 16(4), e0250567. https://doi.org/10.1371/journal.pone.0250567
Mortazavi, S. S., Shati, M., Keshtkar, A., Malakouti, S. K., Bazargan, M., & Assari, S. (2016). Defining polypharmacy in the elderly: A systematic review protocol. BMJ Open, 6(3), e010989. https://doi.org/10.1136/bmjopen-2015-010989
Payne, R. A., Avery, A. J., Duerden, M., Saunders, C. L., Simpson, C. R., & Abel, G. A. (2014). Prevalence of polypharmacy in a Scottish primary care population. European Journal of Clinical Pharmacology, 70(5), 575–581. https://doi.org/10.1007/s00228-013-1639-9
Sarwar, M. R., Dar, A.-R., Mahar, S. Y., Riaz, T., Danish, U., & Iftikhar, S. (2018). Assessment of prescribing potentially inappropriate medications listed in Beers criteria and its association with the unplanned hospitalization: A cross-sectional study in Lahore, Pakistan. Clinical Interventions in Aging, 13, 1485–1495. https://doi.org/10.2147/cia.s173942
Shah, B. M., & Hajjar, E. R. (2012). Polypharmacy, adverse drug reactions, and geriatric syndromes. Clinics in Geriatric Medicine, 28(2), 173–186. https://doi.org/10.1016/j.cger.2012.01.002
Sheikh-Taha, M., & Asmar, M. (2021). Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States. BMC Geriatrics, 21(1), 233. https://doi.org/10.1186/s12877-021-02183-0
Slabaugh, S. L., Maio, V., Templin, M., & Abouzaid, S. (2010). Prevalence and risk of polypharmacy among the elderly in an outpatient setting. Drugs & Aging, 27(12), 1019–1028. https://doi.org/10.2165/11584990-000000000-00000
World Health Organisation. (2018, February 5). Ageing and health. Who.int; World Health Organization: WHO. https://www.who.int/en/news-room/fact-sheets/detail/ageing-and-health
Young, E. H., Pan, S., Yap, A. G., Reveles, K. R., & Bhakta, K. (2021). Polypharmacy prevalence in older adults seen in United States physician offices from 2009 to 2016. PLOS ONE, 16(8), e0255642. https://doi.org/10.1371/journal.pone.0255642
Zhang, N., Sundquist, J., Sundquist, K., & Ji, J. (2020). An Increasing Trend in the Prevalence of Polypharmacy in Sweden: A Nationwide Register-Based Study. Frontiers in Pharmacology, 11. https://doi.org/10.3389/fphar.2020.0032
